Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC)
Shots:
- The P-III KEYNOTE-240 Study involves assessing of Keytruda (200mg- q3w) vs PBO in 413 patients with 1L advance HCC
- The study resulted in unmet 1EPs & 2EPs as OS- PFS & ORR- DOR- disease control rate and time to progression respectively in the trial
- Keytruda (pembrolizumab) 100mg IV is a mAb- used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes
Ref: Merck| Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com